20
Participants
Start Date
February 2, 2024
Primary Completion Date
October 15, 2026
Study Completion Date
October 15, 2026
Valbenazine Oral Capsule
Participants randomized to active treatment will be given a starting dose of 40mg of valbenazine , which may be escalated to 80mg to achieve an optimal dose of the medication for each subject.
Placebo Oral capsule
Participants randomized to placebo will be given a capsule that is the same shape and color as the active medication and will subject to the same dose escalation requirements as the other arm but will receive placebo during the treatment period.
RECRUITING
Yale Child Study Center, New Haven
Collaborators (1)
Neurocrine Biosciences
INDUSTRY
Yale University
OTHER